A doctor’s hand corrects a statement with a pen from “I don’t have actionable…” to “I now have actionable genomic information to better diagnose my patient’s lung disease.” In the background, a CT scan of a lung with a lesion is visible.
A picture of the San Francisco waterfront, where the ATS international conference will take place May 13-18, 2022.
May 13th - 18th 2022, San Francisco, CA
Visit us at booth 1908 to learn about our genomic diagnostic tests for interstitial lung disease and lung cancer. Join our Industry Theaters: May 17th, 12:30-1:00pm – Integrating Novel Genomic Data to Improve ILD Diagnostic and Prognostic Confidence May 17th, 1:30-2:00pm – Integrating the Percepta Genomic Sequencing Classifier for lung nodule risk stratification
Preview of a slide from the webinar showing three 100% stacked bar graphs breaking down number of patients classified as low, intermediate, and high pre-test risk.
View our on-demand webinar
Hear how Dr. Kurman uses Percepta GSC to stratify the risk of primary lung cancer across all pre-test risk groups as a guide for patient management when bronchoscopy is inconclusive.
A picture of the Chicago waterfront, where the ASCO Annual Meeting will take place June 3-7, 2022.
June 3rd-7th | Chicago, IL
Be sure to stop by booth #21085 to learn more about Veracyte’s portfolio of oncology products inclusive of lung cancer
Logo for Envisia Genomic Classifier

Envisia detects genomic UIP pattern to improve ILD diagnostic and prognostic confidence.

Logo for Percepta Lung Cancer Diagnostics portfolio

Percepta GSC stratifies the risk of lung cancer to guide patient management for when bronchoscopy is inconclusive.


Percepta Nasal Swab brings genomic objectivity to lung nodule risk assessment with a simple, non-invasive tool.


Percepta Genomic Atlas guides personalized treatment earlier in lung cancer diagnosis.

Transform uncertainty into confidence

Veracyte offers a suite of actionable genomic tests that can offer greater confidence and clarity at every step of your lung cancer and interstitial lung disease patient management.